Therefore, we compared the expression profiles of the three clusters (Cluster1, Cluster2, and Cluster3) with another published melanoma cohort containing 47 patients who received PD1 inhibitor or CTLA-4 inhibitor using SubMap analysis. This evidence concerns the gene CTLA4 and melanoma.